Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). ITI-2000 HPV+ Tumors. Operating Status Active. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them.
Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent.
Immunomic Therapeutics to Present at Biotech Showcase 2023 The Phase 2 protocol will remain active, the existing Principal Investigators (PIs . ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. Founders Sungwuk Kim. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC).
Immunomic Therapeutics Announces License Agreement With Lineage Cell The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases.
Pipeline - Immunomic Therapeutics Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics.
immunomic therapeutics crunchbase - xarxacatala.cat We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. Immunomic Therapeutics General Information. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571 Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Coordinates: 245831.9N 1213154.0E.
Home - Immunomic Therapeutics Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. View contacts for Immunomic Therapeutics to access new leads and connect with decision-makers. Claim your Free Employer Profile. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Share this article. CONTACT US. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Juniper Point ITI maintains its headquarters in Rockville, Maryland.
Glioblastoma Multiforme (GBM) - Immunomic Therapeutics Mohan Karkada - Director of Research and Development - LinkedIn ROCKVILLE, Md., October 10, 2022--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . Headquarters Location. mcarey@rxir.com We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. Sia Anagnostou MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics, Inc. may be just for you. SaaS, Android, Cloud Computing, Medical Device). CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Founded Date 2015. January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that, Vaccine exclusively delivered with the PharmaJet StratisNeedle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet, a company that engineers precision delivery systems that overcome, November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced, October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today. ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson).
Immunomic Therapeutics Appoints Vice President, Cell Therapy Melssen M.,Vaccines targeting helper T cells for cancer immunotherapy. View detailed 028300.KR description & address. This represents the second closing in the investment process for the HLB Consortium, ($10M was placed in February 2020), and substantially increases their holding in Immunomic Therapeutics to 47.6% of the common stock. No.93, Zhongyang Rd., Xindian Dist., New Taipei City 231, Taiwan. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI maintains its headquarters in Rockville, Maryland. This is the Immunomic Therapeutics company profile. Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. April 23, 2020 04:00 PM Eastern Daylight Time. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. Jan 30, 2015. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. The company was founded in 2005 and is based in Lancaster, Pennsylvania.
Immunomic Therapeutics Inc - Company Profile and News All content is posted anonymously by employees working at Immunomic Therapeutics. aanagnostou@immunomix.com
Teri Heiland - Chief Scientific Officer (CSO) - Immunomic Therapeutics Vaccine technology developed at Johns Hopkins could lead to - Hub For more information, please visit www.immunomix.com. Contact Email info@immunic.de.
News Releases | PharmaJet In addition, ITI-1001 represents a far more cost-effective approach. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. Immunomic Therapeutics Announces Presentation on Nucleic Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs, Northeastern US Biotechnology Female Founded Companies. ITI-1001 is an alternative, cell-free approach to treating GBM. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. We provide a professional and challenging work environment . We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Join to follow . Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. 28 Employees .
We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. To demonstrate our dedication to patients and our understanding of the importance of clinical trials, we have created a . ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them.
15010 Broschart Dr., Suite 110, Rockville, MD 20850. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. Active, Closed, Last funding round type (e.g. Announces Proposed Public Offering of Common Stock, Northeastern US Companies With Fewer Than 1000 Employees (Top 10K), Companies With Fewer Than 100 Employees (Top 10K), United States Companies that Exited (Top 10K), Greater New York Area Biotechnology Companies. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine.
Priscilla Fussell - Legal Counsel, Contracts & Intellectual Property Batich, K.A., Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity.
Immunomic Therapeutics - Overview, News & Competitors | ZoomInfo.com 301-968-3501 Pays for all health and welfare insurance premiums 100%. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips.
Immunomic Therapeutics Strengthens Leadership Team with Appointment of ITI-ID Candidate Multiple infectious diseases. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. November 30, 2021, 7:01 PM UTC. 2016;2016:4857869.
New Taipei Municipal Hsin Tien Senior High School - Wikipedia 858-366-3243, Internet Explorer presents a security risk. ITI-1000 GBM - Cell Therapy. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. Phone Number +119196161923. Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in .
News | Astellas Pharma Inc. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics may be just for you. Company Type For Profit. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Rockville, Maryland, 20850, United States. Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: